ERCC3 and cancer: Unlike triptolide, which induces the degradation of the RPB1 subunit of RNA Pol II, the two molecules promote FBXL18-dependent XPB degradation without causing substantial effects on cancer cell growth, a property that, for spironolactone, correlates with minimal effects on transcription in comparison to triptolide.